Table 2. Comparison of the clinical and pathologic characteristics as well as disease outcome of stage I endometrioid endometrial carcinomas with respect to L1CAM expression.
| All | L1CAM− | L1CAM+ | Pa | |
|---|---|---|---|---|
| Number of patients | 935 | 842 (90%) | 93 (10%) | |
| Median age (years) | 63 (range 32–93) | 63 (range 32–91) | 67 (range 39–93) | <0.01 |
| Median follow-upb (months) | 64 (range 1–210) | 65 (range 1–210) | 55 (range 6–185) | <0.01 |
| Treatment | ||||
| Lymphadenectomy | 586 (63%) | 519 (62%) | 67 (72%) | 0.05 |
| Radiotherapy | 400 (43%) | 359 (43%) | 41 (44%) | 0.79 |
| VBT | 206 (22%) | 189 (23%) | 17 (18%) | |
| EBRT+/−VBT | 190 (20%) | 166 (20%) | 24 (26%) | |
| Chemotherapy | 36 (4%) | 31 (4%) | 5 (5%) | 0.42 |
| Grade | ||||
| 1 | 442 (47%) | 418 (50%) | 24 (26%) | <0.01 |
| 2 | 389 (42%) | 348 (41%) | 41 (44%) | |
| 3 | 104 (11%) | 76 (9%) | 28 (30%) | |
| Myometrial invasion | ||||
| <1/2 | 664 (71%) | 604 (72%) | 60 (65%) | 0.15 |
| ⩾1/2 | 271 (29%) | 238 (28%) | 33 (36%) | |
| LVSI | ||||
| No | 703 (91%) | 645 (92%) | 58 (81%) | <0.01 |
| Yes | 67 (9%) | 53 (8%) | 14 (19%) | |
| Unknown | 165 | 144 | 21 | |
| Outcome | ||||
| Recurrence | 85 (9%) | 66 (8%) | 19 (20%) | <0.01 |
| Locoregional | 48 (5%) | 41 (5%) | 7 (8%) | 0.27 |
| Distant | 42 (5%) | 29 (3%) | 13 (14%) | <0.01 |
| Deceased | 88 (9%) | 69 (8%) | 19 (20%) | <0.01 |
| Endometrial cancer | 37 (4%) | 26 (3%) | 11 (12%) | <0.01 |
Abbreviations: EBRT=external beam radiotherapy; L1CAM=L1 cell adhesion molecule; LVSI=lymphovascular space invasion; VBT=vaginal brachytherapy.
a
P-value for the Mann–Whitney U-test for continuous variables, and χ2 test for categorical variables. Bold values indicate that the differences were considered to be significant.
b
Median follow-up including deceased patients.